Pharmaceuticals, Biotechnology and Life Sciences
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the first quarter…
Continues to be launch ready for PALFORZIATM EU and Swiss regulatory reviews for PALFORZIA remain on schedule Uninterrupted drug supply…
– Conference Call Today at 4:30 p.m. ET – SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell…
Nucleix has appointed new CEO, CFO, General Manager and board member, as it opens San Diego office.
PharmaCyte Biotech said Monday that cGMP Validation, the company’s GMP consultant, is conducting its final audit of the manufacturing facility…
BERKELEY, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other…
AstraZeneca’s and Merck’s Olaparib, Lynparza has been approved in US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer, the companies said Monday in a press release.
Bristol Myers Squib has presented a wide range of research platforms across immunotherapy, cell therapy and protein degradation underscore commitment to advancing cancer research and treatments.